Unecritinib - Chia Tai Tianqing Pharmaceutical Group
Alternative Names: TQ-B3101; Unecritinib fumarate - Chia Tai Tianqing Pharmaceutical GroupLatest Information Update: 17 May 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Acetamides; Antineoplastics; Benzofurans; Chlorobenzenes; Esters; Ethers; Fluorobenzenes; Ketones; Morpholines; Piperidines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein c-met inhibitors; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Non-small cell lung cancer
- No development reported Anaplastic large cell lymphoma
Most Recent Events
- 17 May 2024 Chemical structure information added
- 17 May 2024 No development reported - Phase-II for Anaplastic large cell lymphoma (In adolescents, In children, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater, In adults) in China (PO)
- 30 Apr 2024 Registered for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in China (PO) - First global approval